As resistance to IFNγ signalling could impact therapy efficacy, we screened 59 formalin-fixed, paraffin-embedded (FFPE) tumour samples from patients receiving anti-PD1 therapy for corresponding mutations by targeted sequencing of DNA isolated from macrodissected tumour cells and autologous control blood cells (Table 2). The gene discussed is IFNG; the disease is neoplasm.